ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Update

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 25,624 shares, a decrease of 50.8% from the December 15th total of 52,121 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average daily volume of 43,424 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily volume of 43,424 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.0% of the company’s shares are short sold.

Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF

Several institutional investors have recently modified their holdings of SBIO. Silver Oak Securities Incorporated acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at approximately $677,000. Fulcrum Equity Management acquired a new position in ALPS Medical Breakthroughs ETF during the fourth quarter valued at approximately $384,000. Virtu Financial LLC bought a new stake in ALPS Medical Breakthroughs ETF in the third quarter valued at approximately $650,000. Comerica Bank acquired a new stake in ALPS Medical Breakthroughs ETF in the third quarter worth $27,000. Finally, Sterling Investment Advisors Ltd. acquired a new stake in ALPS Medical Breakthroughs ETF in the third quarter worth $315,000.

ALPS Medical Breakthroughs ETF Stock Down 0.3%

Shares of NYSEARCA:SBIO traded down $0.15 during midday trading on Friday, hitting $51.07. The company had a trading volume of 25,687 shares, compared to its average volume of 51,753. ALPS Medical Breakthroughs ETF has a 12 month low of $22.33 and a 12 month high of $52.90. The firm has a fifty day simple moving average of $49.58 and a 200 day simple moving average of $41.09.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.